Saisheng Pharmaceutical's Urokinase for Injection and Cefixime Tablets Included in the 2026 National Essential Medicines List

Regulation
โดย Jiemian·Read original
Summary · why it matters

Beijing Saisheng Pharmaceutical Co., Ltd. announced that two products from the company and its subsidiaries have been newly added to the National Essential Medicines List, 2026 edition. Urokinase for injection, 100,000 units, is produced by the company, while cefixime tablets, 0.1 grams, are produced by its controlled subsidiary Beijing Saier Biological Pharmaceutical Co., Ltd. The company stated that this is not expected to have a significant impact on operations in the short term, but will positively affect future market expansion, sales growth, and long-term development.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 1

北京赛而生物药业有限公司Private▲ Positive
Regulationrelevance

Cefixime tablets produced by subsidiary newly added to National Essential Medicines List, positively affecting future sales.

© 2026 MarketDXNews